Scott Brown Net Worth

The estimated Net Worth of Scott B. Brown is at least $503 ezer dollars as of 29 December 2022. Mr. Brown owns over 3,500 units of TRACON Pharmaceuticals Inc stock worth over $1,492 and over the last 5 years he sold TCON stock worth over $0. In addition, he makes $501,253 as Chief Accounting Officer at TRACON Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Brown TCON stock SEC Form 4 insiders trading

Scott has made over 5 trades of the TRACON Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 3,500 units of TCON stock worth $5,215 on 29 December 2022.

The largest trade he's ever made was buying 3,500 units of TRACON Pharmaceuticals Inc stock on 29 December 2022 worth over $5,215. On average, Scott trades about 818 units every 60 days since 2020. As of 29 December 2022 he still owns at least 21,628 units of TRACON Pharmaceuticals Inc stock.

You can see the complete history of Mr. Brown stock trades at the bottom of the page.

Scott Brown biography

Scott B. Brown CPA serves as Chief Accounting Officer of the Company. Mr. Brown joined us as Director, Finance and Controller in August 2015, was promoted to Sr. Director, Finance and Controller in January 2017, was promoted to Vice President, Finance in January 2019, and Chief Accounting Officer in September 2019. Prior to joining us, Mr. Brown was Associate Director, Finance at Ardea Biosciences (acquired by AstraZeneca) where he led finance and accounting for Ardea Biosciences as a subsidiary of AstraZeneca from 2013 to 2015. Before that, from 2011 to 2013 Mr. Brown was Finance Manager at SciClone Pharmaceuticals, Inc., and Finance Manager at Exelixis, Inc. from 2009 to 2011. Prior to Exelixis, Mr. Brown held accounting positions of increasing responsibility at AcelRx, Inc., Spinal Elements, Inc., Stewart Title, and as an audit associate for KPMG, LLP. Mr. Brown received a B.S. from the University of California, Santa Barbara, a M.S. in Accountancy from San Diego State University, and is a Certified Public Accountant licensed in the state of California.

What is the salary of Scott Brown?

As the Chief Accounting Officer of TRACON Pharmaceuticals Inc, the total compensation of Scott Brown at TRACON Pharmaceuticals Inc is $501,253. There are 4 executives at TRACON Pharmaceuticals Inc getting paid more, with Charles Theuer having the highest compensation of $1,085,320.

How old is Scott Brown?

Scott Brown is 40, he's been the Chief Accounting Officer of TRACON Pharmaceuticals Inc since 2019. There are 13 older and no younger executives at TRACON Pharmaceuticals Inc. The oldest executive at TRACON Pharmaceuticals Inc is William LaRue, 69, who is the Independent Director.

What's Scott Brown's mailing address?

Scott's mailing address filed with the SEC is C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO, CA, 92122.

Insiders trading at TRACON Pharmaceuticals Inc

Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.

What does TRACON Pharmaceuticals Inc do?

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w

Complete history of Mr. Brown stock trades at TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc executives and stock owners

TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Charles Theuer,
  President, Chief Executive Officer, Director
• Dr. Charles P. Theuer M.D., Ph.D.,
  CEO, Pres & Director
• Mark Wiggins,
  Chief Business Officer
• Mark C. Wiggins M.B.A.,
  Chief Bus. Officer
• Scott Brown,
  Chief Accounting Officer
• Scott B. Brown CPA, M.S.,
  Chief Financial Officer
• Suzy Benedict,
  Executive Vice President - Regulatory Affairs
• Stephen Worland,
  Independent Director
• J. Rainer Twiford,
  Independent Director
• Martin Mattingly,
  Independent Director
• William LaRue,
  Independent Director
• Saundra Pelletier,
  Director
• Bonne Adams,
  Executive Vice President - Clinical Operations
• Dr. Brenda Marczi Pharm.D., Pharmd Mba,
  Sr. VP of Regulatory Affairs
• Ya Huang,
  Exec. Director of Statistical Programming
• Bonne Adams,
  Exec. VP of Clinical Operations
• Dr. James L. Freddo,
  Chief Medical Officer
• Shahe Garabedian,
  Sr. VP & Head of Quality Assurance
• Ravi Nea Partners 14, L.P.N...,
  
• Peter W.Nea Partners 14, L....,
  
• Scott Dnea Partners 14, L.P...,
  
• Patrick Jnea Partners 14, L...,
  
• David Mnea Partners 14, L.P...,
  
• Anthony A. Jr.Nea Partners ...,
  
• Forestnea Partners 14, L.P....,
  
• Peter Jnea Partners 14, L.P...,
  
• M Jamesnea Partners 14, L.P...,
  
• Capital, Llc Ikarian Health...,
  
• Patricia L Bitar,
  CFO
• Forest Baskett,
  10% owner
• Patrick J Kerins,
  10% owner
• H Casey Logan,
  Chief Business Officer
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• David M Mott,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Enterprise Associates 14, L...,
  
• Tracon Investment Fund Ii, ...,
  
• Paul Edward Walker,
  Director
• Ronald L Shazer,
  Chief Medical Officer
• Krishna Kittu Kolluri,
  10% owner
• Ravi Viswanathan,
  10% owner
• Theodore T Wang,
  Director
• Cross Border Opportunities ...,
  
• Cross Border Opportunities ...,
  
• Harry R Weller,
  10% owner
• Enterprise Associates 14, L...,
  
• Ryan D Drant,
  10% owner
• Super V3 Investment Limited...,
  10% owner
• Management Inc. Opaleye,
  10% owner
• Capital, Llc Ikarian Health...,
  
• Lisa Johnson Pratt,
  Director
• Carol C. Lam,
  Director